Kala Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call
May 09 2022 - 8:00AM
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage
biopharmaceutical company focused on the discovery, development and
commercialization of innovative therapies for diseases of the eye,
today announced that it will report first quarter 2022 financial
results on Monday, May 16, 2022. Management will host a conference
call and live audio webcast to discuss these results and provide a
business update at 8:00 a.m. ET.
The dial-in numbers to access this conference call are
866-300-4091 (domestic) or 703-736-7433 (international) using the
conference ID 6384677. To access a live webcast and subsequent
archived recording of the call, please visit “Events” in the
“Investors” section on the Kala website at http://kalarx.com/.
About Kala Pharmaceuticals, Inc.
Kala is a commercial-stage biopharmaceutical company focused on
the discovery, development, and commercialization of innovative
therapies for diseases of the eye. Kala has applied its
AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery
Technology to two ocular therapies, EYSUVIS® (loteprednol
etabonate ophthalmic suspension) 0.25% and
INVELTYS® (loteprednol etabonate ophthalmic suspension) 1%.
The Company also has a pipeline of development programs including a
clinical-stage secretome product candidate, KPI-012, initially
targeting persistent corneal epithelial defects (PCED) and multiple
proprietary new chemical entity (NCE) preclinical development
programs targeted to address unmet medical needs, including both
front and back of the eye diseases. For more information on Kala,
please visit www.kalarx.com.
Investor Contacts:
Jill Steierjill.steier@kalarx.com 781-996-5252
Hannah Deresiewiczhannah.deresiewicz@sternir.com
212-362-1200
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From Aug 2024 to Sep 2024
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From Sep 2023 to Sep 2024